A Real-Life Survivability Story & “Special” Greed | Eli-Lilly Pharmaceuticals Loses USD 15 billion after Fake Twitter Account ‘insulin is free’ Tweet.

Billionaire Elon Musk’s changes to social media giant Twitter are already costing some companies, investors and ordinary people tens of billions of dollars.

Pharmaceutical company Eli Lilly (LLY) dipped 4.37 per cent Friday to US $352.30 — erasing over US $15 billion in market cap — after a Twitter Blue verified account impersonating the brand promised free insulin.

The tweet, sent around 1:30 p.m. Thursday, read: “We are excited to announce insulin is free now.” The post remained online for hours, attracting over 3,000 likes and hundreds of retweets.

It is highly likely that the twitter impersonator(s) responsible are activists who wanted to expose Eli Lilly for breaking laws and gauging customers over decades. In one case back in 2009, Lilly was fined $1.4 billion in the Zyprexa case but found a way to negotiate with regulators It is worth noting an out of court settlement.

It is worth noting that the three people who discovered insulin, a life-saving drug, originally sold their patents to the University of Toronto for $1 each. One of the team members, Sir Frederick G. Banting, remarked: “Insulin does not belong to me, it belongs to the world.”

Click on image to see “Survivability” on Amazon.

“Banting selling his rights to the University of Toronto for one dollar was a noble act – it was his gift to humanity. His gift and ethos got hijacked by the unapologetic pure capitalist greed of profitability 1st and at any cost, minimum government regulation, and without any ‘Social Responsibility’ requirement.”

“This untamed greed caused the world the 2008 global financial crisis, and many other global disasters.”

Khaled Fattal, Survivability News Publisher 

Fattal addresses these and many other critical issues in great depth and detail in his recently published International Best-Selling Book “Survivability“.

As of Friday, the impostor account @EliLillyandCo is no longer verified, its tweets have been set to private. The official Eli Lilly account responded Thursday afternoon with an apology, confirming that “Our official Twitter account is @LillyPad.”

In response, Musk has reportedly suspended Twitter Blue sign-ups as of Friday afternoon, less than 48 hours after the launch. The move was to “help address impersonation issues,” according to an internal memo obtained by Zoë Schiffer of Platformer.

Confused users can tell who was verified before Twitter Blue and who paid $8 for the privilege by clicking on the checkmark in people’s profiles. Musk also confirmed the rollout of “official” badges for notable companies and other entities — a grey badge found under the user’s name.

Eli Lilly, along with drugmakers Novo Nordisk and Sanofi, currently dominate the insulin market. Together, they account for the entire insulin supply in the U.S. and 90 per cent worldwide.

Worth noting, Eli Lilly was the first company to mass-manufacture insulin, shipping its first commercial supply in 1923.  today, in 2022, the company charges $82.41 for individual vials of their Insulin Lispro Injection, or $159.12 for a pack of five pens.

Are you Citizen-Journalist Material?

Have a tip or scoop? Do you have info about corruption that needs to be investigated and responsibly exposed ? Get in touch securely via WhatsApp at +44 7771 927378 | Signal at +447766 098270


Receive Exclusives, Features & News Updates

Subscribe



What Are
Geo-Poli-
Cyber™ Risks?

What Is Geo-Poli-Cyber™?

MLi Group created the terms Poli-Cyber™ and Geo-Poli-Cyber™ (GPC™) in 2012 and 2013 based on the philosophy that if you cannot identify and name the threat, you cannot mitigate that threat.

Geo-Poli-Cyber™ attacks are political, ideological, terrorist, extremist, ‘religious’, and/or geo-politically motivated.

More Sinister Than Financial Motivations

Geo-Poli-Cyber™ attacks are significantly different from financially motivated cyber-attacks in damage, scale, magnitude as well as in risk mitigation strategies and solutions.

Click to read more